Home Cart Sign in  
Chemical Structure| 928672-86-0 Chemical Structure| 928672-86-0

Structure of Canagliflozin hemihydrate
CAS No.: 928672-86-0

Chemical Structure| 928672-86-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Canagliflozin hemihydrate (JNJ28431754 hemihydrate) is a selective SGLT2 inhibitor with IC50 values of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.

Synonyms: JNJ 28431754 hemihydrate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Canagliflozin hemihydrate

CAS No. :928672-86-0
Formula : C48H52F2O11S2
M.W : 907.05
SMILES Code : O[C@H]1[C@H](C2=CC=C(C)C(CC3=CC=C(C4=CC=C(F)C=C4)S3)=C2)O[C@H](CO)[C@@H](O)[C@@H]1O.[H]O[H].O[C@H]5[C@H](C6=CC=C(C)C(CC7=CC=C(C8=CC=C(F)C=C8)S7)=C6)O[C@H](CO)[C@@H](O)[C@@H]5O
Synonyms :
JNJ 28431754 hemihydrate
MDL No. :MFCD28975933
InChI Key :VHOFTEAWFCUTOS-TUGBYPPCSA-N
Pubchem ID :24997615

Safety of Canagliflozin hemihydrate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
AML12 cells 40 µM 24 hours To evaluate the effect of CANA on FFA-induced steatosis in AML12 cells, the results showed that CANA significantly reduced lipid accumulation. PMC9916118
J774A.1 cells 10 µM 1 hour To evaluate the effect of CANA on LPS and nigericin-induced pyroptosis in J774A.1 cells, the results showed that CANA significantly reduced the expression of pyroptosis-related proteins. PMC9916118
Rat pulmonary artery smooth muscle cells (rPASMCs) 0.5 μM to 20 μM 24 hours To evaluate the effect of CANA on rPASMCs proliferation, results showed that CANA significantly inhibited rPASMCs proliferation under hypoxic conditions. PMC11335861

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice ob/ob mice and diabetic mice Oral gavage 10 mg/kg/d Once daily for 14 weeks To evaluate the effect of CANA on the progression of NAFLD in ob/ob mice and diabetic mice, the results showed that CANA improved insulin sensitivity, hepatic steatosis, and inflammation. PMC9916118
Mice and rats Hypoxia-induced pulmonary hypertension (PH) model and Sugen 5416/hypoxia-induced severe PH model Oral 10 mg/kg (mice) and 5 mg/kg (rats) Once daily for 21 days To evaluate the therapeutic effect of CANA on pulmonary hypertension, results showed that CANA significantly reduced pulmonary artery pressure, right ventricular hypertrophy, and vascular remodeling. PMC11335861

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.10mL

0.22mL

0.11mL

5.51mL

1.10mL

0.55mL

11.02mL

2.21mL

1.10mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories